Market Tracker

05/24 5:16pm ET

Biomarin Pharmaceutical Inc (NASDAQ:BMRN)

87.95
Delayed Data
As of 3:59pm ET
 +2.44 / +2.85%
Today’s Change
62.12
Today|||52-Week Range
151.75
-16.05%
Year-to-Date
Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
May 20 / Zacks.com - Paid Partner Content
3 Risky Biotechs With FDA Decisions On Deck -- Are They Buys?
May 12 / MotleyFool.com - Paid Partner Content
Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
May 16 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close85.51
Today’s open86.32
Day’s range86.16 - 88.88
Volume911,752
Average volume (3 months)1,789,773
Market cap$13.9B
Dividend yield--
Data as of 3:59pm ET, 05/24/2016

Growth & Valuation

Earnings growth (last year)-16.30%
Earnings growth (this year)-105.34%
Earnings growth (next 5 years)+25.00%
Revenue growth (last year)+16.29%
P/E ratioNM
Price/Sales19.22
Price/Book5.75

Competitors

 Today’s
change
Today’s
% change
INCYIncyte Corp+0.59+0.73%
PRGOPerrigo Company PLC+2.76+2.95%
MDVNMedivation Inc+1.16+1.91%
VRXValeant Pharmaceutic...-0.10-0.38%
Data as of 4:02pm ET, 05/24/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)-$0.50
Annual revenue (last year)$872.2M
Annual profit (last year)-$171.8M
Net profit margin-19.70%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Jean-Jacques Bienaimé
Chief Financial Officer &
Executive Vice President
Daniel K. Spiegelman
Corporate headquarters
San Rafael, California

Forecasts